On Oct. 23rd, 2023, MediLink Therapeutics is pleased to announce the appointment of Dr. Steve Chin as Chief Medical Officer (CMO). Dr. Chin will be responsible for MediLink’s clinical trial execution, product registration and optimization of clinical capability in both China and the US.
Dr. Steve Chin
Dr. Chin is a seasoned expert in clinical oncology with a wealth of experience in global cancer therapeutic development. He previously served as CMO at Elpiscience Biopharma, a company focused on developing next-generation cancer immunotherapies. There, Dr. Chin provided leadership and technical guidance in the development of clinical strategy to ensure quality execution of 6 new clinical programs (primarily early-phase/first-in-human). Before joining Elpiscience, Dr. Chin was a Senior Medical Director of immuno-oncology, Global Clinical Development at AstraZeneca. He was involved in the successful development of durvalumab registration trials, including Topas-1, Emerald-2, and Kunlun. Prior to AstraZeneca, Dr. Chin was a Global GI Oncology Lead at Eli Lilly. He was involved in the transfer of cetuximab (Erbitux) full rights in North America from BMS to Lilly and the regulatory submission of Erbitux sBLA in KRAS wild-type, metastatic colorectal cancer.
Dr. Chin started his career as a medical oncologist at the Medical University of South Carolina in Charleston. Over his academic career, Dr. Chin served as PI or Co-I in over 20 active clinical trials.
"It is with great honor and excitement that I join the MediLink family as CMO," said Dr. Chin. "As one of the leading companies in antibody-drug conjugates (ADC), MediLink has developed a rich product pipeline. I will work closely with our internal colleagues and external partners to bring more innovative products to cancer patients."
Dr. Tony Xue, Chairman and CEO of MediLink, said: "We warmly welcome Dr. Chin to join our team. MediLink already has two projects undergoing clinical research in China and the United States, and has launched a series of domestic and foreign cooperation. We believe that Dr. Chin will further enhance our international R&D capabilities and promote MediLink’s innovative technologies and products to benefit cancer patients around the world.”
About MediLink Therapeutics
MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary Tumor Microenvironment Activable LINker-payload (TMALIN®) ADC technology platform. It can generate homogeneous ADC, and further improve the therapeutic window in treatment of solid tumors. We focus clinical drug development on unmet medical needs and will continuously expand into new disease areas to serve the global patients.
Our headquarter is located in Suzhou and has established R&D subsidiaries in Shanghai and Boston.
MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech
MediLink Therapeutics Announces Latest Business Progress with Nona Biosciences